Skip to main content

Advertisement

SpringerLink
Log in

Behçet’s disease: Recent advances in early diagnosis and effective treatment

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Behçet’s disease (BD) is a chronic, multisystem, inflammatory disorder that is classified among the systemic vasculitidies. Its cause has yet to be determined, but genetic and environmental factors and immune dysregulation are thought to play a role in its pathogenesis. The diagnosis of the disease and recognition and separation from disorders that may mimic BD may be difficult, especially in areas where the disease is uncommon. Certainty as to the best treatments for the various manifestations of BD is often unclear due to limited randomized controlled trials. However, existing consensus statements and expert opinions should help to guide therapy. This review examines important recent contributions to help the clinician more readily recognize patients with the disease and institute appropriate care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Calamia K, Wilson F, Icen M, et al.: Epidemiology and clinical characteristics of Behcet’s disease in the United States: A population-based study [abstract]. Clin Exp Rheumatol 2008, 26(3 Suppl 50):A12.

    Google Scholar 

  2. Shahram F, Nadji A, Chams H, et al.: Epidemiological data from the Iran Registry of Behcet’s Disease, report of 6,128 cases [abstract]. Clin Exp Rheumatol 2008, 26(3 Suppl 50):A11.

    Google Scholar 

  3. Mizuki N, Meguro A, Tohnai I, et al.: Association of major histocompatibility complex class I chain-related gene A and HLA-B alleles with Behcet’s disease in Turkey. Jpn J Ophthalmol 2007, 51:431–436.

    Article  PubMed  Google Scholar 

  4. Gul A, Hajeer AH, Worthington J, et al.: Evidence for linkage of the HLA-B locus in Behcet’s disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001, 44:239–240.

    Article  PubMed  CAS  Google Scholar 

  5. Mahr A, de Menthon M, LaValley M, Guillevin L: HLA-B5 (1) and risk of Behcet’s disease: a meta-analysis of genetic association studies [abstract]. Clin Exp Rheumatol 2008, 26(3 Suppl 50):A8.

    Google Scholar 

  6. Gul A, Hajeer AH, Worthington J, et al.: Linkage mapping of a novel susceptibility locus for Behcet’s disease to chromosome 6p22–23. Arthritis Rheum 2001, 44:2693–2696.

    Article  PubMed  CAS  Google Scholar 

  7. Karasneh J, Gul A, Ollier WE, et al.: Whole-genome screening for susceptibility genes in multicase families with Behcet’s disease. Arthritis Rheum 2005, 52:1836–1842.

    Article  PubMed  CAS  Google Scholar 

  8. Gul A: Behcet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005, 4:81–83.

    Article  PubMed  Google Scholar 

  9. Atagunduz P, Ergun T, Direskeneli H: MEFV mutations are increased in Behcet’s disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003, 21(4 Suppl 30):S35–S37.

    PubMed  CAS  Google Scholar 

  10. Kone-Paut I, Sanchez E, Le Quellec A, et al.: Autoinflammatory gene mutations in Behcet’s disease. Ann Rheum Dis 2007, 66:832–834.

    Article  PubMed  CAS  Google Scholar 

  11. Direskeneli H: Autoimmunity vs autoinflammation in Behcet’s disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 2006, 45:1461–1465.

    Article  CAS  Google Scholar 

  12. Ryan JG, Goldbach-Mansky R: The spectrum of autoin-flammatory diseases: recent bench to bedside observations. Curr Opin Rheumatol 2008, 20:66–75.

    PubMed  Google Scholar 

  13. Kalayciyan A, Zouboulis C: An update on Behcet’s disease. J Eur Acad Dermatol Venereol 2007, 21:1–10.

    Article  PubMed  CAS  Google Scholar 

  14. Mumcu G, Inanc N, Yavuz S, Direskeneli H: The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behcet’s disease. Clin Exp Rheumatol 2007, 25(4 Suppl 45):S27–S33.

    PubMed  CAS  Google Scholar 

  15. Yi SW, Kim EH, Kang HY, et al.: Erythema nodosum: clinicopathologic correlations and their use in differential diagnosis. Yonsei Med J 2007, 48:601–608.

    Article  PubMed  Google Scholar 

  16. Ilknur T, Pabuccuoglu U, Akin C, et al.: Histopathologic and direct immunofluorescence findings of the papulopustular lesions in Behcet’s disease. Eur J Dermatol 2006, 16:146–150.

    PubMed  Google Scholar 

  17. Boyvat A, Heper AO, Kocyigit P, et al.: Can specific vessel-based papulopustular lesions of Behcet’s disease be differentiated from nonspecific follicular-based lesions clinically? Int J Dermatol 2006, 45:814–818.

    Article  PubMed  Google Scholar 

  18. Ozdemir M, Bodur S, Engin B, Baysal I: Evaluation of application of multiple needle pricks on the pathergy reaction. Int J Dermatol 2008, 47:335–338.

    Article  PubMed  Google Scholar 

  19. Davatchi F, Chams-Davatchi C, Shahram F, et al.: Changes in incidence of pathergy phenomenon in Behcet’s disease over time [abstract]. Clin Exp Rheumatol 2008, 26(3 Suppl 50):A3.

    Google Scholar 

  20. Pandrea A, Rudinskaya A, Klein B, Krebs T: What does it take to diagnose Behcet disease?. J Clin Rheumatol 2007, 13:31–34.

    Article  PubMed  Google Scholar 

  21. Diri E, Espinoza LR: Neuro-Behcet’s syndrome: differential diagnosis and management. Curr Rheumatol Rep 2006, 8:317–322.

    Article  PubMed  Google Scholar 

  22. International Study Group for Behçet’s Disease: Criteria for diagnosis of Behcet’s disease. Lancet 1990, 335:1078–1080.

    Google Scholar 

  23. Zouboulis CC: Adamantiades-Behçet disease. In Fitzpatrick’s Dermatology in General Medicine, 7th edn. Edited by Wolff K, Goldsmith L, Katz S, et al.: New York: The McGraw-Hill Companies, Inc.; 2008: 1620–1626.

    Google Scholar 

  24. Schirmer M, Calamia KT, O’Duffy D: Is there a place for large-vessel disease in the diagnostic criteria for Behçet’s disease. J Rheumatol 1999, 26:2511–2512.

    PubMed  CAS  Google Scholar 

  25. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005, 352:351–361.

    Article  Google Scholar 

  26. Hoffman GS, Cid MC, Rendt-Zagar KE, et al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621–630.

    PubMed  Google Scholar 

  27. Melikoglu M, Fresko I, Mat C, et al.: Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol 2005, 32:98–105.

    PubMed  CAS  Google Scholar 

  28. Sfikakis PP, Markomichelakis N, Alpsoy E, et al.: Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations. Rheumatology (Oxford) 2007, 46:736–741.

    Article  CAS  Google Scholar 

  29. Tognon S, Graziani G, Marcolongo R: Anti-TNF-alpha therapy in seven patients with Behcet’s uveitis: advantages and controversial aspects. Ann N Y Acad Sci 2007, 1110:474–484.

    Article  PubMed  CAS  Google Scholar 

  30. Niccoli L, Nannini C, Benucci M, et al.: Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford) 2007, 46:1161–1164.

    Article  CAS  Google Scholar 

  31. Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I: Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease. J Ocul Pharmacol Ther 2007, 23:395–401.

    Article  PubMed  CAS  Google Scholar 

  32. Atmaca LS, Yalcindag FN, Ozdemir O: Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behcet’s disease. Graefes Arch Clin Exp Ophthalmol 2007, 245:451–456.

    Article  PubMed  CAS  Google Scholar 

  33. Hatemi G, Silman A, Bang D, et al.: EULAR recommendations for the management of Behcet’s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2008, (Jan 31 Epub ahead of print).

  34. Kotter I, Eckstein AK, Stubiger N, Zierhut M: Treatment of ocular symptoms of Behcet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 1998, 82:488–494.

    Article  PubMed  CAS  Google Scholar 

  35. Kötter I, Zierhut M, Eckstein AK, et al.: Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003, 87:423–431.

    Article  PubMed  Google Scholar 

  36. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M: Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006, 244:1692–1695.

    Article  PubMed  CAS  Google Scholar 

  37. Bodaghi B, Gendron G, Wechsler B, et al.: Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007, 91:335–339.

    Article  PubMed  Google Scholar 

  38. Krause L, Altenburg A, Pleyer U, et al.: Longterm visual prognosis of patients with ocular Adamantiades-Behcet’s disease treated with interferon-alpha-2a. J Rheumatol 2008, 35:896–903.

    PubMed  CAS  Google Scholar 

  39. Kotter I, Vonthein R, Zierhut M, et al.: Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004, 33:311–319.

    Article  PubMed  CAS  Google Scholar 

  40. Kotter I, Gunaydin I, Zierhut M, Stubiger N: The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004, 33:320–335.

    Article  PubMed  CAS  Google Scholar 

  41. Kotter I, Gunaydin I, Batra M, et al.: CNS involvement occurs more frequently in patients with Behcet’s disease under cyclosporin A (CSA) than under other medications—results of a retrospective analysis of 117 cases. Clin Rheumatol 2006, 25:482–486.

    Article  PubMed  Google Scholar 

  42. Kobayashi K, Ueno F, Bito S, et al.: Development of consensus statements for the diagnosis and management of intestinal Behcet’s disease using a modified Delphi approach. J Gastroenterol 2007, 42:737–745.

    Article  PubMed  Google Scholar 

  43. Choi IJ, Kim JS, Cha SD, et al.: Long-term clinical course and prognostic factors in intestinal Behçt’s disease. Dis Colon Rectum 2000, 43:692–700.

    Article  PubMed  CAS  Google Scholar 

  44. Chou SJ, Chen VT, Jan HC, et al.: Intestinal perforations in Behcet’s disease. J Gastrointest Surg 2007, 11:508–514.

    Article  PubMed  Google Scholar 

  45. Choi CH, Kim TI, Kim BC, et al.: Anti-Saccharomyces cerevisiae antibody in intestinal Behcet’s disease patients: relation to clinical course. Dis Colon Rectum 2006, 49:1849–1859.

    Article  PubMed  Google Scholar 

  46. Monselise A, Weinberger A, Monselise Y, et al.: Anti-Saccharomyces cerevisiae antibodies in Behcet’s disease—a familial study. Clin Exp Rheumatol 2006, 24(5 Suppl 42):S87–S90.

    PubMed  CAS  Google Scholar 

  47. Ahn JK, Lee YS, Jeon CH, et al.: Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008, 27:201–205.

    Article  PubMed  Google Scholar 

  48. Korkmaz C: Is anticoagulation unnecessary in Behcet’s disease with deep venous thrombosis? Clin Rheumatol 2008, 27:405–406.

    Article  PubMed  Google Scholar 

  49. Pipitone N, Olivieri I, Padula A, et al.: Infliximab for the treatment of neuro-Behcet’s disease: a case series and review of the literature. Arthritis Rheum 2008, 59:285–290.

    Article  PubMed  CAS  Google Scholar 

  50. Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, et al.: Interferon-{alpha}—a new therapeutic option in refractory juvenile Behcet’s disease with CNS involvement. Rheumatology (Oxford) 2008 (in press).

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL, 32224, USA

    Kenneth T. Calamia

Authors
  1. Kenneth T. Calamia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Phaedon G. Kaklamanis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth T. Calamia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calamia, K.T., Kaklamanis, P.G. Behçet’s disease: Recent advances in early diagnosis and effective treatment. Curr Rheumatol Rep 10, 349–355 (2008). https://doi.org/10.1007/s11926-008-0057-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-008-0057-y

Keywords

Search

Navigation